Search company, investor...


Founded Year




Total Raised


Date of IPO


About Ikonisys

Ikonisys enables early, accurate and non-invasive disease detection with diagnostic medicine. Through a combination of technology and science, Ikonisys is dedicated to helping physicians and researchers realize the promise of rare cell detection to give patients the best chance of managing their disease. The company has developed and refined its CellOptics platform, the foundation for Ikonisys' products and services, enabling the transformation of non-invasive cell-based diagnostics to rare cell detection. These products enable large and regional reference labs, hospitals, research institutions and practice groups to reduce the risk of human error, lower costs, and expand test volume capacity.

Headquarters Location

5 Science Park Suite 1000

New Haven, Connecticut, 06511,

United States


Missing: Ikonisys's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Ikonisys's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Ikonisys

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ikonisys is included in 2 Expert Collections, including Medical Devices.


Medical Devices

8,565 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,901 items

Ikonisys Patents

Ikonisys has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Microscopy, Molecular biology, Genetics, Cell imaging, Cell biology


Application Date


Grant Date



Related Topics

Microscopy, Molecular biology, Genetics, Cell imaging, Cell biology



Latest Ikonisys News

Ikonisys SA (von Sphene Capital GmbH): Buy

Oct 12, 2022

12.10.2022 | 11:42 Nachricht : *Erforderliche Felder ^Original-Research: Ikonisys SA - von Sphene Capital GmbHEinstufung von Sphene Capital GmbH zu Ikonisys SAUnternehmen: Ikonisys SAISIN: FR00140048X2Anlass der Studie: Update ReportEmpfehlung: Buyseit: 12.10.2022Kursziel: EUR 6,70 (bisher EUR 6,90)Kursziel auf Sicht von: 24 MonateLetzte Ratingänderung: -Analyst: Peter Thilo Hasler, CEFAMandatory convertible bond The issuance of a mandatory convertible bond with warrants attachedprovides Ikonisys with the liquidity needed for the global commercialroll-out strategy of the Ikoniscope20 and the further development of themicroscopy platform into a state-of-the-art Artificial Intelligence system,in our view. In addition, Ikonisys expands the shareholder base by aninstitutional London-based investor, specialised in tailor-made financingsolutions for small and medium-sized companies. Based on a three-stepdiscounted cash flow entity model (primary valuation method) and includingthe funds from the convertible bond and the warrants, we calculate a fullydiluted price target of EUR 6.70 per share and confirm our Buy rating forthe shares of Ikonisys SA.Die vollständige Analyse können Sie hier downloaden: Kontakt für RückfragenPeter Thilo Hasler, CEFA+49 (89) 74443558/ +49 (152)übermittelt durch die EQS Group AG.-------------------Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw.Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatungoder Aufforderung zum Abschluss bestimmter Börsengeschäfte.° © dpa-AFX 2022

Ikonisys Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ikonisys Rank

Ikonisys Frequently Asked Questions (FAQ)

  • When was Ikonisys founded?

    Ikonisys was founded in 1999.

  • Where is Ikonisys's headquarters?

    Ikonisys's headquarters is located at 5 Science Park, New Haven.

  • What is Ikonisys's latest funding round?

    Ikonisys's latest funding round is IPO.

  • How much did Ikonisys raise?

    Ikonisys raised a total of $45.23M.

  • Who are the investors of Ikonisys?

    Investors of Ikonisys include Trevi Health Ventures, New Science Ventures, Lakeview Capital, Ludl Electronic Products, Palisade Capital Management and 6 more.

  • Who are Ikonisys's competitors?

    Competitors of Ikonisys include Oxford BioDynamics, AutoGenomics, Orison, Michelson Diagnostics, Molecular Detection and 12 more.

Compare Ikonisys to Competitors


Diamics, Inc. is a medical device and diagnostics company. The company is developing, manufacturing, and marketing cost effective cancer diagnostic systems that will increase long-term cancer survival rates through early detection.

Stage I Diagnostics Logo
Stage I Diagnostics

Stage I Diagnostics is a cancer biotechnology company focused on providing early stage diagnosis provided by new biomarkers deployed through In-Vitro Diagnostics (IVD). The company's initial focus is the early diagnosis of ovarian cancer. Stage I's core competency is the process of converting newly discovered genes into commercial products which impact clinical decisions. The company's approach is to determine what characteristics new biomarkers should have to achieve the best diagnostic results in targeted diseases and then to discover what genes exist that fit those characteristics. This process has led us to not only discover and patent numerous genes associated with various types of cancer but also clone 4 new genes.

Modules for Novel Diagnostics

MND Diagnostics is a healthcare company focused on disease diagnosis. The medical device company has developed a diagnostic detection platform which aims to be rapid, low-priced and portable.

Binx Health Logo
Binx Health

Binx Health is an in vitro diagnostics Point-of-Care (POC) company that provides at-home STI testing. The platform also includes evidence-based testing, counseling, treatment, and follow up in order to increase screening and reduce infections.


Quadraspec is changing the face of diagnostic medicine. Quadraspec's patented SDI label-free detection technology aims to permit the rapid analysis of up to 100 unique tests on up to 1,000 unique patients per hour. Quadraspec's , multiplex-capable diagnostics platform aims to allow high throughput, label-free, highly sensitive bioassays, and diagnostics.

Dilon Technologies

Dilon Technologies is a medical device manufacturer that focuses on products that assist in the fight against breast cancer. The company offers a portfolio of medical devices that includes the Navigator System, a trusted brand and world-renowned surgical gamma probe for radio-guided lymphatic mapping and tumor localization, the MarginProbe, a groundbreaking technology for accurate microscopic margin assessment in breast cancer surgery, and the TrueView 100 Pro, a Specimen Radiography System (SRS) that uses advanced radiography and automated software to precisely identify tumor lesions in resected or biopsied breast tissue. The company was founded in 1999 and is based in Newport News, Virginia.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.